Acrux Ltd has released a press release.
4th FDA ANDA approval received - Dapsone Gel, 5%
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Acrux
- Appendix 4D and Half Year Report
- Quarterly Activities / Appendix 4C Cashflow Report
- Gedeon Richter buyout Lenzetto Royalties for EUR4.1million
- Launch of prilocaine and lidocaine cream in United States
- Mutual Termination of Co-Development Agreement
Later from Acrux
- Acruxs seventh generic dossier accepted by FDA for review
- Activities Statement and Appendix 4C
- Appendix 4E and FY23 Annual Report
- Investor Presentation - Acrux FY23 Results
- Acrux receives $2.88m R&D Tax Incentive Rebate for FY23
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux